Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$40.82 USD
-0.18 (-0.44%)
Updated May 29, 2024 04:00 PM ET
After-Market: $40.80 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/07/2024
Time: -- |
6/2024 | $-0.59 | 26.50% |
Earnings Summary
For their last quarter, Cerevel Therapeutics (CERE) reported earnings of -$0.73 per share, missing the Zacks Consensus Estimate of -$0.61 per share. This reflects a negative earnings surprise of 19.67%. Look out for CERE's next earnings release expected on August 07, 2024. For the next earning release, we expect the company to report earnings of -$0.59 per share, reflecting a year-over-year increase of 6.35%.
Earnings History
Price & Consensus
Zacks News for CERE
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services